Wilson Disease Drugs Market Research, 2031
The global wilson disease drugs market size was valued at $595.2 million in 2021, and is projected to reach $848.2 million by 2031, growing at a CAGR of 3.6% from 2022 to 2031. Wilson’s disease (WD) is an inherited disorder in which defective biliary excretion of copper leads to its accumulation, particularly in the liver and brain. The disease is progressive and, if left untreated, may cause liver (hepatic) disease, central nervous system dysfunction, and death. Early diagnosis and treatment may prevent serious long-term disability and life-threatening complications. The features of this condition include a combination of liver disease and neurological and psychiatric problems.
Affected people often experience a variety of neurologic (central nervous system-related) signs and symptoms, as well. Neurologic features often develop after the liver has retained a significant amount of copper; however, they have been seen in people with little to no liver damage. These symptoms may include tremors, muscle stiffness, and problems with speech, swallowing, and/or physical coordination. Almost all people with neurologic symptoms have Keyser–Fleisher rings – a rusty brown ring around the cornea of the eye that can best be viewed using an ophthalmologist’s slit lamp.
Treatment for Wilson’s disease is life-long and aimed at lowering copper levels to nontoxic levels, and at preventing the progression of the disease, and trying to reverse any signs and symptoms that have appeared because of copper accumulation in the body. Treatment may be divided into three parts: first treatment of symptomatic patients; second, maintenance therapy after the copper has been reduced in affected tissues; and third, in asymptomatic patients, maintenance therapy may be used from the beginning.
The several promising novel therapies, including chelators targeting specific cell types and cell-based and gene therapies, may revolutionize the care for WD patients. However, timely clinical diagnosis remains the main challenge, and many unmet needs exist because of possible clinical deterioration in treated patients.
Increase in demand for Wilson disease drugs market size is anticipated to increase globally during the forecast period, owing to increase in the prevalence of Wilson disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis. In addition, the increase in investment by players in R&D and presence of robust pipeline candidates, rise in expenditure on the development of healthcare infrastructure, increase in public awareness about the disease prevention in developing regions further drive Wilson disease drugs market growth. However, lack of awareness and diagnosis facility associated with Wilson disease treatment and high treatment cost due to complications restrain the wilson disease drugs industry growth. Conversely, high investment by the government for drug development and increase in healthcare expenditure are expected to offer lucrative wilson disease drugs market opportunity opportunities for the key player in the market.
The Wilson disease drugs market is segmented on the basis of drug type, distribution channel and region. On the basis of drug type, the market is bifurcated into Penicillamine, Trientine and Zinc. On the distribution channel, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy. Furthermore, on the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Global Wilson disease drugs market by drug type
By drug type, the Wilson disease drugs market is divided into Penicillamine, Trientine and Zinc. The Penicillamine segment was the major revenue contributor of wilson disease drugs market share in 2021, and is anticipated to continue this trend during the forecast period, owing to increase in Wilson disease incidence and the pharmaceutical industry and research organizations have been forced to concentrate on the discovery of a treatment for Wilson disease. In addition, key players' ongoing research initiatives and the deployment of innovative technology in this market as well as significant government and private sector funding in the Wilson disease research which further boost the market growth. On the other side, Trientine segment is projected to exhibit the fastest market growth during the forecast period, owing to the Increase in approval of Wilson’s disease treatment drugs by regulatory authority. In addition, increase in healthcare expenditure and government support and initiatives taken by the countries to work on R&D activities for Wilson disease drugs development which further boost growth of wilson disease drugs industry.
By Drug Type
Penicillamine segment dominated the market in 2021, and is expected to continue this trend during the forecast period
Global Wilson disease drugs market by distribution channel
By distribution channel, the market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment was the major revenue contributor of wilson disease drugs market share 2021, and is anticipated to continue this trend during the wilson disease drugs market forecast , owing to increase in Wilson disease patients, the growing number of independent pharmacies and chains along with the availability of medications in supermarkets & mass retailers Furthermore, the rapid adoption of automation technologies, such as pharmacy robots, dispensing, and packaging systems is driving the segment growth.
By Distribution Channel
Retail pharmacy segment was the highest contributor to the market in 2021
Global Wilson disease drugs market by region
By region, the Wilson disease drugs market is analyzed across North America, Asia-Pacific, Europe, and LAMEA. North America dominated the market in 2021, accounting for the highest share, and is anticipated to maintain this trend during the forecast period. Owing to investments made by the key players for various R&D activities as well as launch of new products in the U.S. In addition, increase awareness among the consumers for the adoption of Wilson disease drugs further boost the market growth.
By Region
North America accounted for a mojority of the global market share in 2021, and is anticipated to remain dominant during forecast period
The major companies profiled in the report include ANI Pharmaceuticals, Inc., APOTEX, Bausch Health Companies Inc., Breckenridge Pharmaceutical, Inc., Dr. Reddy's Laboratories Ltd, Lupin Limited, NAVINTA LLC, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Vivet Therapeutics.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the wilson disease drugs market analysis from 2021 to 2031 to identify the prevailing wilson disease drugs market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the wilson disease drugs market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global wilson disease drugs market trends, key players, market segments, application areas, and market growth strategies.
Wilson Disease Drugs Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 848.2 million |
 Growth Rate | CAGR of 3.6% |
 Forecast period | 2021 - 2031 |
 Report Pages | 211 |
 By Distribution Channel |
|
 By Drug Type |
|
 By Region |
|
 Key Market Players | DR.REDDY'S LABORATORIES LTD, Navinta LLC, ANI Pharmaceuticals, Inc., Breckenridge Pharmaceutical, Inc., Panacea Biotec Ltd, Bausch Health Companies Inc., Par pharmaceutical, Lupin, Apotex, Teva Pharmaceutical Industries Limited |
Analyst Review
This section provides opinions of the CXOs of key companies operating in the Wilson disease drugs. According to CXOs, the Wilson disease drugs market has gained momentum in the research, innovation, and development sectors, owing to surge in advancements in Wilson disease drugs and surge in product launch by key players. In addition, high demand for Wilson disease drugs and pipeline products which boost the market growth. Moreover, rise in awareness about Wilson disease and increase in number of novel drug manufactures are some factors which further boost the market growth. Emerging economies in Asia-Pacific and LAMEA are expected to present lucrative growth opportunities to key players in the industry, owing to surge in demand for drug discovery.
According to perspectives of CXOs of leading companies, demand for Wilson disease drugs has significantly increase, owing to increase in Wilson disease population and surge in R&D of products of Wilson disease. Moreover, short duration of time, high accuracy, and precision of the drugs propels the market growth However, high cost of treatments associated with Wilson disease may hamper the market growth.
The CXOs further added that North America is expected to remain dominant during the forecast period, owing to factors such as increase in presence of key players. Moreover, Asia-Pacific are expected to offer lucrative opportunities to the market during the forecast period, owing to availability of various diagnostic services for Wilson disease patients and rise in R&D pipeline products.
The total market value of Wilson disease drugs market is $595.17 million in 2021.
The market value of Wilson disease drugs market in 2031 is $848.19 million.
increase in the prevalence of Wilson disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis drive the growth of the market.
Top companies such as ANI Pharmaceuticals, Inc., APOTEX, Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd, Lupin Limited, Pfizer Inc. and Teva Pharmaceutical Industries Ltd. held a high market position in 2021.
Asia-Pacific is expected to experience the highest growth rate during the forecast period, owing to The presence of a large population base, increasing per capita income and growing medical tourism industry.
Loading Table Of Content...
Loading Research Methodology...
